Business Context and Reporting Period
Axsome Therapeutics, Inc. filed this Form 8-K on July 12, 2016, to disclose a material accounting error requiring the restatement of previously issued financial statements. The error pertains to the fiscal year ended December 31, 2015, and the quarter ended March 31, 2016.
Key Financial Metrics and Material Changes
The filing identifies a specific accounting correction regarding a non-cash $1.65 million premium associated with convertible notes converted in November 2015. This amount should have been recorded directly to additional paid-in capital rather than as interest or other income/expense.
- Net Loss Impact: Previously reported net loss for the year ended December 31, 2015, was understated by $1.65 million.
- Interest and Other Income (Expense): Previously reported figures for the year ended December 31, 2015, were understated by $1.65 million.
- Cash Flow and Liquidity: The correction has no impact on the Company's cash, total assets, total stockholders' equity, loss from operations, or total cash flows.
- Balance Sheet Adjustments: Restatements will adjust additional paid-in capital and accumulated deficit for periods ending December 31, 2015, and March 31, 2016.
Guidance, Outlook, and Management Commentary
Management and the Audit Committee, in consultation with independent auditors Ernst & Young, LLP, concluded that the financial statements in the 2015 Form 10-K and the March 2016 Form 10-Q should no longer be relied upon. The Company intends to file amendments to both reports to restate the affected financial statements. No forward-looking guidance or new operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the upcoming amended Form 10-K for the year ended December 31, 2015.
- Verify the upcoming amended Form 10-Q for the quarter ended March 31, 2016.
- Confirm that the $1.65 million adjustment is reclassified to additional paid-in capital in the restated filings.
- Note that cash flow and liquidity metrics remain unchanged despite the net loss restatement.